Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 5, 2003, Pages 261-271

  Waterhouse, Dawn N ^a,b   Gelmon, Karen A ^a   Masin, Dana ^a   Bally, Marcel B ^a,b,c  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Celator Technologies Inc   (Canada)

Author keywords

Combination drug therapy; Liposomal encapsulation; P185; Treatment outcome

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MDA MB 435; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOWN-REGULATION; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0347624649     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1533-869X.2003.01099.x     Document Type: Article

References (44)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Bohn U, Aguiar J, Bilbao C, Murias A, Vega V, Chrino R, Diaz-Chico N, Diaz-Chico JC. Prognostic value of the quantitative measurement of the oncoprotein p185 (Her-2/neu) in a group of patients with breast cancer and positive node involvement. Int J Cancer 101: 539-544, 2002.
3. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340-1349, 1998.
4. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79: 216-223, 2002.
5. Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21: 1022-1028, 2003.
6. Ye J, Xu RH, Taylor-Papadimitriou J, Pitha PM. Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of a2-integrin expression in human mammary epithelial cells. Mol Cell Biol 16: 6178-6189, 1996.
7. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. ER2 (neu) signalling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
8. Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263-2270, 1992.
9. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8, 1997.
10. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + /MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17: 98, 1998.
11. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin™ (humanized anti-her2 antibody) as a single agent in 222 women with her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17: 97, 1998.
12. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26: 96-101, 1999.
13. Garratt AN, Özcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 13: 80-86, 2003.
14. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate oligodeoxynucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 7: 189-198, 1999.
15. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr. A placebo-controlled trial of ICAM-1 antisense oligodeoxynucleotide in the treatment of Crohn's disease. Gastroenterology 114: 1133-1142, 1998.
16. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137-1141, 1997.
17. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotides, in combination with chemotherapy in refractory or relapsed acute leukaemia. Blood 101: 425-432, 2003.
18. Tolcher AW, Reyno L, Venner PM, et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8: 2530-2535, 2002.
19. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6: 2492-2500, 2000.
20. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6: 2891-2902, 2000.
21. Saxon DN, Lutwyche P, Webb M, Bally MB. Downregulation of HER-2/neu by an anti-HER-2/neu phosphorothioate oligonucleotide and its use in combination with doxorubicin for treatment of breast cancer xenograft models. Proc Am Assoc Cancer Res 40: 480, 1999.
22. Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligodeoxynucleotides. Nucleic Acids Res 24: 4558-4564, 1996.
23. Liu X, Pogo BG. Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 6: 9-16, 1996.
24. Roh H, Pippin J, Boswell C, Drebin JA. Antisense oligodeoxynucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res 77: 85-90, 1998.
25. Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery 126: 413-421, 1999.
26. Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam NDrebin JA. HER2/neu antisense targeting of human breast carcinoma. Oncogene 11: 6138-6143, 2000.
27. Uedo N, Tatsuta MBaba M, et al. Inhibition by rat C-erbB-2/ neu antisense oligonucleotide of gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer 83: 670-673, 1999.
28. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 8: 475-486, 2002.
29. Semple SC, Klimuk SK, Harasym TO, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small muftilamellar multilamellar vesicle structures. Biochim Biophys Acta 78005: 1-15, 2000.
30. Pool GL, French ME, Edwards RA, Huang L, Lumb RH. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids 17: 448-452, 1982.
31. Paik S, King CR, Simpson S, Lippman ME. Quantification of erbB-2/neu levels in tissue. Methods Enzymol 198: 290-300, 1991.
32. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365, 1996.
33. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligodeoxynucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 1812-1823, 2000.
34. Emerson DL, Bendele R, Brown E, et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 6 (7): 2903-2912, 2000.
35. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71: 482-488, 1995.
36. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72: 896-904, 1995.
37. Saxon D, Chia SK, Bally MB. Drug combinations for therapy of aggressive breast cancer: antisense oligodeoxynucleotides against HER-2/neu. Biological therapy of breast cancer. Oncology 1: 7-11, 2000.
38. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489: 31-44, 1999.
39. Jansen B, Wacheck V, Heere-Reess E, et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728-1733, 2000.
40. Webb MS, Saxon D, Wong FM, et al. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372: 272-282, 1998.
41. Agrawal S, Kandimalla ER. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Target 1: 197-209, 2001.
42. Mui B, Raney SG, Semple SC, Hope MJ. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther 298: 1185-1192, 2001.
43. Monteith DK, Levin AA. Synthetic oligodeoxynudeotides: the development of antisense therapeutics. Toxicol Pathol 27: 8-13, 1999.
44. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Tolcher A. A phase I trial of an antisense oligonucleotide to BCL-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 19: 330, 2000.